May 17, 2019

Alexandria Ocasio-Cortez Went After Big Pharma for Getting Rich off Anti-HIV Drugs. A Republican Began to Cry.

What costs $8 a month in Australia costs almost $2,000 a month in the United States.

Tom Williams / ZUMA

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.

Alexandria Ocasio-Cortez has a knack for getting under conservatives’ skin. She happens to also be able to make them cry.

At a House Oversight and Reform Committee hearing Thursday, Ocasio-Cortez asked Daniel O’Day, chairman and CEO of the pharmaceutical company Gilead, why an HIV prevention drug costs nearly $2,000 a month in the United States but only $8 in Australia. Gilead said that the drug is still under patent protection in the US, but Ocasio-Cortez pointed out that the patent for the drug is owned by the public.

Ocasio-Cortez’s questions caused former Ted Cruz staffer Chip Roy, a Republican representative from Texas, to get visibly upset. Speaking about a medicine that he took to cure his Hodgkin’s lymphoma, Roy said private pharmaceutical companies deserve the profits they earn.

“To sit here and attack the capitalistic system that produces and distributes medicine to saving lives around the world, I mean, it is just offensive,” Roy said. Addressing Gilead, he added, “I hope you make a lot of money!”

Watch Ocasio-Cortez’s questioning and Roy’s statements below.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate